Cantor Fitzgerald Forecasts ESPR FY2026 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Esperion Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earn $0.02 per share for the year. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The firm had revenue of $65.00 million for the quarter, compared to the consensus estimate of $54.97 million.

A number of other research analysts also recently commented on ESPR. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Friday, April 25th. Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Esperion Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $6.25.

Esperion Therapeutics Trading Down 2.5%

Shares of NASDAQ ESPR traded down $0.03 on Wednesday, reaching $1.17. 2,145,207 shares of the company traded hands, compared to its average volume of 5,267,507. Esperion Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $3.94. The company has a 50 day moving average of $0.96 and a 200 day moving average of $1.65. The stock has a market capitalization of $231.89 million, a PE ratio of -1.83 and a beta of 0.67.

Institutional Trading of Esperion Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. J.W. Cole Advisors Inc. acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $66,000. Sigma Planning Corp grew its position in Esperion Therapeutics by 1,455.8% in the fourth quarter. Sigma Planning Corp now owns 190,441 shares of the biopharmaceutical company's stock valued at $419,000 after acquiring an additional 178,200 shares in the last quarter. Summit Wealth Group LLC grew its position in Esperion Therapeutics by 292.5% in the fourth quarter. Summit Wealth Group LLC now owns 157,000 shares of the biopharmaceutical company's stock valued at $345,000 after acquiring an additional 117,000 shares in the last quarter. Victory Capital Management Inc. grew its position in Esperion Therapeutics by 602.8% in the fourth quarter. Victory Capital Management Inc. now owns 173,083 shares of the biopharmaceutical company's stock valued at $381,000 after acquiring an additional 148,456 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $98,000. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.